CSTL — Castle Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $864.83m
- $615.46m
- $219.79m
- 87
- 33
- 86
- 77
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 51.9 | 62.6 | 94.1 | 137 | 220 |
Cost of Revenue | |||||
Gross Profit | 44.6 | 53 | 78.3 | 105 | 175 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 39.3 | 70.6 | 134 | 210 | 288 |
Operating Profit | 12.5 | -7.94 | -40.1 | -72.9 | -68 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 5.35 | -10.2 | -40 | -68.9 | -57.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5.28 | -10.3 | -31.3 | -67.1 | -57.5 |
Net Income Before Extraordinary Items | |||||
Net Income | 5.28 | -10.3 | -31.3 | -67.1 | -57.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.99 | -10.3 | -31.3 | -67.1 | -57.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.126 | -0.495 | -1.24 | -2.58 | -2.14 |